Dietary proteins are known to carry a wide range of nutritional, functional and biological properties. Nutritionally, the proteins are a source of energy and amino acids, which are essential for growth and maintenance. Functionally, the proteins contribute to the physicochemical and sensory properties of various protein-rich foods. Furthermore, many dietary proteins possess specific biological properties which make these components potential ingredients of functional or health-promoting foods. Many of these properties are attributed to physiologically active peptides encrypted in protein molecules.
INTRODUCTION
In recent years, the role of proteins in the diet as physiologically active components has been increasingly acknowledged. Such proteins or their precursors may occur naturally in raw food materials exerting their physiological action direct or upon enzymatic hydrolysis in vitro or in vivo. In this context, it has become clear that dietary proteins are a source of biologically active peptides. These peptides are inactive within the sequence of parent protein and can be released during gastrointestinal digestion or food processing. Once bioactive peptides are liberated, they may cause different physiological functions. Milk proteins are the most important source of bioactive peptides, though other animal as well as plant proteins are also known to contain potential bioactive sequences [1] [2] [3] [4] .
During the last twenty years, the knowledge of bioactive peptides has steadily increased, and at present numerous peptides exhibiting various activities -such as opiate, antithrombotic or anti-hypertension activity, immunomodulation or as relative to mineral utilization properties have been reported. This activity is based on the inherent amino acid composition and sequence. Bioactive peptides usually contain 3 -20 amino acid residues per molecule. Many milkderived peptides reveal multi-functional properties, i.e., specific peptide sequences may initiate two or more different biological activities. Due to their physiological and physicochemical versatility, milk-borne bioactive peptides are regarded as highly prominent ingredients for healthpromoting functional foods or pharmaceutical preparations. The formation and properties of milk protein-derived peptides have been reviewed in many recent articles [5] [6] [7] [8] [9] .
Peptides with biological activity can be produced from milk proteins in three ways: a) enzymatic hydrolysis with digestive enzymes, b) fermentation of milk with proteolytic starter cultures and c) through the action of enzymes derived from proteolytic microorganisms. During controlled fermentation of milk with certain dairy starters, peptides with various bioactivities can be formed, and these are detected in an active form even in the final products, such as fermented milks and cheese [5, 9, 10] . Thus, such traditional dairy products may under certain conditions carry specific health effects when ingested as part of the daily diet. Also, these peptides are likely to be produced industrially in the future in the form of hydrolysates or peptide mixtures which can be used as ingredients for various dietary or pharmaceutical products. This article will review the current knowledge about bioactive peptides derived from various proteins, with emphasis on their potential applications for designing healthpromoting functional foods.
FUNCTIONALITY OF BIOACTIVE PEPTIDES
The first bioactive peptides to be mentioned are the caseinophosphopeptides (CPPs) by Mellander in 1950, when he suggested that casein-derived phosphorylated peptides enhanced vitamin D-independent bone calcification in rachitic infants [11] . Bovine α s1 -, α s2 -and β-casein contain phosphorylated regions which can be released. Specific CPPs can form soluble organophosphate salts and may function as carriers for different minerals, especially calcium. Published data on the effect of CPP on mineral solubility and absorption are inconsistent, partly due to the diversity of the experimental approaches. For example, Saito et al. [12] suggested that Ca content in the diet might be an important factor in determining the effect of CPP on Ca absorption. Peptides with opioid activity are found in milk protein and wheat gluten hydrolysates [13, 14] . Opioid peptides are opioid receptor ligands with agonistic or antagonistic activities. β-casein opioid peptides (β-casomorphins) have been detected in the duodenal chyme of minipigs and in the human small intestine as a consequence of in vivo digestion of casein or milk. Opioid peptides can be considered as compounds having possible effects on the nervous system. Opioid peptides are reported to influence gastrointestinal function in two ways: first, they affect smooth muscles, which reduces transit time, and second, they affect the intestinal transport of electrolytes, which explains their antisecretory properties. Angiotensin I-converting enzyme (ACE, peptidyldipeptide hydrolase, EC 3.4.15.1) has been associated with the renin-angiotensin system, which regulates peripheral blood pressure. Inhibition of this enzyme can exert an anti-hypertensive effect. ACE-inhibitory peptides have been isolated from the enzymatic digest of various food proteins and are, at present, the most studied bioactive peptide group [15, 16] . Milk protein-derived peptides are known to have an effect on the cells of the immune system, as well as on downstream immunological responses and cellular functions. Immunomodulating casein peptides have been found to stimulate the proliferation of human lymphocytes and the phagocytic activities of macrophages [17] [18] [19] [20] . Antimicrobial peptides have been purified from several bovine milk hydrolysates. The most studied are the lactoferricins, derived from bovine and human lactoferrin. These peptides exhibit antimicrobial activity against various Gram-positive and -negative bacteria, yeast and filamentous fungi. Disruption of normal membrane permeability is at least partly responsible for the antibacterial mechanism of lactoferricins [21, 22] . In addition, α s2 -casein, α-lactalbumin (α-la) and β-lactoglobulin (β-lg) contain several antibacterial polypeptide fragments [23] [24] [25] [26] . The α-la and β-lg-derived polypeptides were, for the most part, active against Gram-positive bacteria, while Gram-negative bacteria were only poorly susceptible to the bactericidal action of the polypeptides. Bacillus subtilis was the most susceptible bacterial strain to the action of these peptides. In addition to milk-derived peptides, an antimicrobial peptide has been identified from hen ovotransferrin. This peptide showed strong bactericidal activity against Staphylococcus aureus and Escherichia coli strains [27] . Recent studies have shown that antioxidative peptides can be released from casein. Peptides derived from α s -casein have been shown to have free radical-scavenging activity and to inhibit enzymatic and non-enzymatic lipid peroxidation [28, 29, 30] . Nagaoka et al. [31] identified a novel hypocholesterolemic peptide (Ile-Ile-Ala-Glu-Lys) from the tryptic hydrolysate of β-lg. This peptide suppressed in vitro cholesterol absorption by Caco-2 cells, also eliciting hypocholesterolemic activity in vivo in rats upon oral administration of the peptide solution. In the test group, total cholesterol levels in serum were significantly lower, whereas high-density lipoprotein (HDL) cholesterol concentration and the atherogenic index were significantly higher than in the control groups fed a diet containing casein tryptic hydrolysate or β-sitosterol. The mechanism of the hypocholesterolemic effect remains to be elucidated. Recently, a peptide with anxiolytic-like stress relieving properties was identified in the casein hydrolysate. This α s1 -casein derived peptide [f (91) (92) (93) (94) (95) (96) (97) (98) (99) (100) ] has been demonstrated to be active not only in animal model studies but in human ones as well [32] .
Some of the peptides derived from milk proteins have more than one functional role; e.g., peptides from the sequence 60−70 of β-casein show immunostimulatory, opioid and ACE-inhibitory activities. This sequence has been defined as a strategic zone [33] . The sequence is protected from proteolysis because of its high hydrophobicity and the presence of proline residues. It has further been reported that α s1 -casein fraction (194−199) shows immunomodulatory and ACE-inhibitory activity [17, 34] . Also, the opioid peptides α-and β-lactorphin have been found to exhibit ACEinhibitory activity [35] [36] [37] . As phosphopeptides also have immunomodulatory properties [38, 39] , it can be concluded that many of the known bioactive peptides have more than one functional property, at least in vitro.
MEANS OF PRODUCTION OF BIOACTIVE PEPTIDES
There are a number of methods by which peptides with biological activity can be produced from precursor proteins. The most common ones are (a) enzymatic hydrolysis with digestive enzymes, (b) by means of the microbial activity of fermented foods or (c) through the action of enzymes derived from proteolytic micro-organisms. Once the structure of bioactive peptides is known, it is also possible to synthesize peptides. Three main approaches are available at present: (1) chemical synthesis; (2) recombinant DNA technology; and (3) enzymatic synthesis [40] .
Enzymatic Digestion
Up to this point, enzymatic hydrolysis of proteins has been the most common way to produce bioactive peptides. Pancreatic enzymes, preferably trypsin, have been used for the chemical characterisation and identification of many known bioactive peptides. For example, ACE-inhibitory peptides as well as CPPs are most commonly produced by trypsin [41, 42] . On the other hand, other enzymes and different enzyme combinations of proteinases-including alcalase, chymotrypsin, pancreatin and pepsin as well as enzymes from bacterial and fungal sources-have been utilised to generate bioactive peptides. Microbial enzymes have also been successfully used to generate ACE-inhibitory peptides [43, 44] . Higher yields of CPPs and, in particular, higher amounts of α s1 -casein f in the hydrolysate have been obtained with casein micelles successively digested with pepsin and trypsin than from acid-precipitated casein and casein micelles by tryptic digestion alone [45] . Peptides derived from other than milk proteins have been successfully produced by thermolysin and trypsin, as shown in (Table 1) . For example, several hypotensive peptides have been identified from porcine skeletal muscle and corn protein after digestion with thermolysin [46] [47] [48] .
Peptide Synthesis
The selection of the most suitable method for peptide synthesis depends mainly on the length and quantity of the desired peptide. The total enzymatic synthesis is currently limited to relatively short sequences. On the other hand, recombinant DNA technology is the preferred choice for relatively large peptides and is suited to products consisting of up to several hundred amino acids. Currently, the most widely used approach to the synthesis of peptides on the laboratory scale is the chemical one. Two variants of this methodology exists, namely liquid-phase and solid-phase synthesis. The solid-phase approach is still the most powerful method for synthesis of peptides composed of about 10 to over 100 residues on a small scale, as well as for the rapid production of peptide libraries for screening purposes [40] .
The application of recombinant DNA technology typically requires a long and expensive research and development phase, but once the system is established the product can be obtained in large quantities from very inexpensive starting materials via fermentation. Attempts to extend this approach to the preparation of short peptides have not yet been truly successful. For example, the expression of the opioid pentapeptide sequence L- [Leu 5 ]-enkephalin (Tyr-Gly-Gly-Phe-Leu) in Arabidopsis thaliana and Brassica napus albumin seed storage proteins, followed by proteolytic digestion of the fusion proteins with trypsin, provided the desired pentapeptide with a yield of only 50-200 nmol (28-112 µg) gram -1 seed [49] . β-Casomorphins, both human and bovine, have been produced by genetic engineering techniques. The genes were cloned into a plasmid and transformed to E.coli. The fusion with a host Gelatin (Alaska Pollack skin) Alcalase, Pronase E Gly-Glu-Hyp-Gly-Pro-Hyp-Gly-ProHis-Gly-Pro-Hyp-Gly-Pro-Hyp-Gly Gly-Pro-Hyp-Gly-Pro-Hyp-Gly-ProHyp-Gly-Pro-Hyp-Gly Antioxidative [132] Chicken Thermolysin Ile-Lys-Trp Leu-Lys-Pro ACE-inhibition Antihypertensive [133] Egg ovalbumin Chymotrypsin Pepsin
Pepsin
Arg-Ala-Asp-His-Pro-Phe Leu-Trp Glu-Arg-Lys-Ile-Lys-Val-Tyr-Leu Phe-Arg-Ala-Asp-His-Pro-Phe-Leu Vasodilatation ACE-inhibition Antihypertensive Antihypertensive [134] [133] [135] protein was used to protect peptides from proteolytic degradation. In the final step, the required peptides were cleaved from the fusion protein by enzymatic or chemical methods. The concentration of β-casomorphin in the culture medium was estimated to be 38.22 nmol/l [50, 51] . The sequence encoding antihypertensive peptide, Arg-Pro-LeuLys-Pro-Trp, has been introduced into the gene for soybean β-conglycin α'subunit. This subunit was expressed in E. coli, recovered from the soluble fraction and purified by chromatography. The Arg-Pro-Leu-Lys-Pro-Trp peptide was released from recombinant containing subunit after digestion by trypsin and chymotrypsin [52] . Feeney et al. [53] reported that the construction of glutenin genes and their expression in E.coli is a viable method for producing peptides. In addition, Kim et al. [54, 55] have succeeded in expressing recombinant human α s1 -casein in E. coli and to purify it. The trypsin digest of this protein contained several ACEinhibitory peptides. Furthermore, genetic engineering can be used to produce enzymes having specific activity in such a manner that they are able to release the desired peptides from the precursor proteins.
Despite significant advances, the synthesis of short sequences using genetic engineering methods often remains impractical, due to the low expression efficiencies obtained and difficulties encountered in product extraction and recovery.
PRODUCTION OF BIOACTIVE PEPTIDES BY ENZYMATIC HYDROLYSIS
Hydrolysis can be performed by conventional batch hydrolysis or by continuous hydrolysis using ultrafiltration membranes. The traditional batch method has several disadvantages, such as the relatively high cost of the enzymes and their inefficiency compared to a continuous process, as noted in numerous studies [56, 57] . The enzymatic membrane reactor, which integrates enzymatic hydrolysis, product separation and catalyst recovery into a single operation, is an attractive configuration for this purpose. It has already been widely applied to total conversion of food proteins of various origins, in order to produce hydrolysates with improved nutritional and/or functional properties [58, 59] . Ultrafiltration membrane reactors have been shown to improve the efficiency of enzyme-catalysed bioconversion, increase product yields and be easily scaled up. Furthermore, ultrafiltration membrane reactors yield a consistently uniform product with desired molecular mass characteristics [56] . Ultrafiltration steps using low molecular mass cut-off membranes may be useful to separate small peptides from high molecular mass residues and remaining enzymes. Visser et al. [60] studied the degradation of bovine β-casein by plasmin in a membrane recycle reactor for the continuous production and isolation of peptide fractions. Turgeon and Gauthier [61] used a two-step ultrafiltration process, and were able to produce a mixture of polypeptides and a fraction rich in small peptides, with molecular mass below 2000 Da.
In the last few years, the use of membrane reactors for the continuous production of specific peptidic sequences has been reported [62, 63] . This approach requires i) highly specific enzymes; ii) better control of the enzymatic reaction; and iii) highly selective membranes to separate the desired peptide from the reaction mixture. Continuous extraction of bioactive peptides in membrane reactors has been mainly applied to milk proteins. Several papers have demonstrated the feasibility of continuous production of caseinomacropeptide (CMP)-derived antithrombotic peptides in an ultrafiltration enzymatic membrane reactor [59, 64] . In those studies, they were able to produce 2.65 g of small bioactive peptides from 34 g of CMP; however, the purity of the final product was not as expected, due to the transmission of high molecular mass peptides (M r > 6200 Da). In addition, they showed that the overall hydrolytic process occurs via two consecutive reactions,where the hydrolysis of the third bond is controlled by the accumulation of the intermediary products. Such accumulation depends on enzyme concentration, substrate concentration, and substrate feeding flow rate. By means of these parameters, the extent of the sequential reactions can be controlled by preventing or enhancing the concentration of intermediary fragments at the steady state of the continuous membrane reactor.
Righetti et al. [65] proposed a multicompartment enzyme reactor operating under an electric field, for the continuous hydrolysis of milk proteins. This set-up allows for continuous harvesting of some biologically active peptides, e.g., phosphopeptides and precursors of casomorphins in a pure form, using trypsin to digest β-casein.
Perea and Ugalde [58] utilized a membrane recycle reactor in hydrolysing whey protein with alcalase under varying enzyme to substrate ratios and residence times. This continuous hydrolysis offered great practical advantages in terms of enzyme yield, productivity, and conversion levels with respect to batch process. In addition, aspects related to product homogeneity may also be improved with this system: simple controls of conversion, ensured peptide products of known chain length within reasonably narrow range and reproducibility. They considered that this system is suitable for the production of peptides with specific functional and nutritional properties. However, the application of this system may be limited as a result of the relatively high cost of the filtration units and the relatively short reactor stability obtained. Bordenave et al. [66] demonstrated that α-lactorphin was successfully generated with continuous hydrolysis of goat whey in an ultrafiltration reactor. Gauthier and Pouliot [67] combined enzymatic hydrolysis and ultrafiltration in order to produce emulsifying peptides from β-lg. They noted the occurrences of severe fouling problem associated with peptide-membrane interactions, especially in ultrafiltration of casein hydrolysates. Therefore, a better understanding of the surface properties of the ultrafiltration membranes is critical for the development of new and specific applications in the fraction of milk protein hydrolysates.
On the other hand, peptides can be isolated by ionexchange membranes. In a method described by Recio and Visser [68] , the protein of interest was concentrated within a chromatographic medium and hydrolysed in situ with an appropriate enzyme. The resulting active peptides were retained on the ion-exchanger, while other peptides were washed out. Finally, the fraction containing the active peptides is eluted from chromatographic medium. With this method, they have been able to isolate and enrich cationic antibacterial peptides from lactoferrin and α s2 -casein, as well as negatively charged phosphopeptides from β-casein. The advantage of this process is that isolation of the precursor protein is unnecessary, which significantly reduces production cost. Furthermore, since the enzyme used in this process can be recovered, the price of the final product can be further decreased. These techniques provide new possibilities for enriching peptides with low molecular masses, and are easily up-scaled to gram or even kilogram quantities [68, 69] .
After hydrolysis, the peptides in the hydrolysates can be fractionated and enriched through the use of various methods. For example, following tryptic digestion, CPPs are isolated by isoelectric precipitation of residual casein, followed by scalable methods such as selective precipitation [70] or ultrafiltration [71] . However, these methods produce products of low purity. Adamson and Reynolds [70] succeeded in producing high-purity CPP by applying selective precipitation of CPPs using 100 mM CaCl 2 and 50% (v/v) ethanol. The most selective procedures for isolating CPPs involve chromatography, but these methods produce a fairly low CPP yield [42, 72] . Ellegård et al. [73] developed a process-scale isolation method of high-purity CPPs using acid precipitation, diafiltration and anion exchange chromatography.
Ultrafiltration membranes have been successfully incorporated to enrich specific peptide fractions [60, 61, 74, 75] . Pihlanto-Leppälä et al. [76] applied selective ultrafiltration membranes (30 kDa and 1 kDa) for the enrichment of opioid peptides, α-lactorphin and β-lactorphin from pepsinhydrolysed α-la and pepsin and trypsin hydrolysed β-lg, respectively. We have reported that the < 1 kDa fractions from α-la hydrolysed with pepsin or β-lg hydrolysed either with pepsin and trypsin or with pepsin, trypsin and chymotrypsin exhibit ACE-inhibitory activity which was, in many cases, higher than in the other fractions tested [77] . These results, together with those of Mullally et al. [78] suggest that it may be possible to exploit ultrafiltration to enrich ACE-inhibitory peptides derived from whey protein.
Fujita et al. [79] showed that ultrafiltration of thermolysin digest of dried bonito, demonstrates more potent antihypertensive effects in hypertensive subjects compared to hydrolysate. Both these products contained the same peptide sequence (Leu-LysPro-Asn-Met) as active compound.
Berot et al. [80] showed an ultrafiltration process allowing the fractionation of wheat hydrolysates. They used an inorganic ZrO 2 -based membrane at acidic pH, and fractionation was primarily due to charge and hydrophobicity effects whereas size effects were only marginal. Martin-Orue et al. [81] studied the separation mechanism of amino acid and peptide solutions, and they indicated that two parameters should be accounted: the molecular weight and the number of co-ionic and counter-ionic groups. This suggests that further attention should be given to the study of electrophoretic mobility in regard to solutes as a criterion of fractionation. Table 2 enlists some of the above mentioned methods applied for generation and concentration of bioactive peptides from milk proteins.
FORMATION OF BIOACTIVE PEPTIDES BY MICROBIAL FERMENTATION
Many industrially used dairy starter cultures are highly proteolytic. This property is traditionally exploited by the dairy industry, as the peptides and amino acids degraded from milk proteins during fermentation contribute to the typical flavour, aroma and texture of the products. The proteolytic system of lactic acid bacteria, such as Lactococcus lactis, Lactobacillus helveticus and Lactobacillus delbrueckii var. bulgaricus, is already well known [82, 83] . This system consists of a cell wall-bound proteinase and several intracellular peptidases. In recent years, rapid progress has been made in the elucidation of the biochemical and genetic characterization of these enzymes [84] . At least 16 peptidases responsible for the conversion of the released peptides into free amino acids have been characterized from lactic acid bacteria [85] . Williams et al. [86] showed that the activities of peptidases are affected by growth conditions. The proteolytic system of lactic acid Selective membrane ultrafiltration (30 kDa → 1 kDa)
α-lactalbumin β-lactoglobulin
Opioid and ACE-inhibitory peptides [76] [77] [78] Acid precipitation, diafiltration, anionexchange chromatography Casein Phosphopeptides [73] bacteria provides transport systems specific for amino acids, di-and tripeptides and oligopeptides of up to 18 amino acids. Longer oligopeptides which are not transported into the cells can be a source for the liberation of bioactive peptides in fermented milk products when further degraded by intracellular peptidases after cell lysis [83] . In the gastrointestinal tract, digestive enzymes may further degrade long oligopeptides, leading to a possible release of bioactive peptides. Once liberated in the intestine, bioactive peptides may act locally or pass through the intestinal wall into blood circulation ending up in a target organ, with subsequent regulation of physiological conditions through, e.g., nerve, immune, vascular or endocrine systems. Table 3 enlists experimental studies in which the release of bioactive peptides has been observed upon fermentation of milk, whey or casein fractions using different live proteolytic microorganisms or proteolytic enzymes as derived from such microorganisms.
The release by microbial fermentation of various bioactive peptides from milk proteins has been reported in many studies. Nakamura et al. [87, 88] identified two ACEinhibitory peptides (Val-Pro-Pro, Ile-Pro-Pro) in milk fermented with a starter culture composed of L. helveticus and Saccharomyces cerevisiae. Pihlanto-Leppälä et al. [89] studied the potential formation of ACE-inhibitory peptides from cheese whey and caseins during fermentation, with various commercial lactic acid starters used in the manufacture of yoghurt, ropy milk and sour milk. No ACEinhibitory activity was observed in these hydrolysates. Further digestion of above samples with pepsin and trypsin resulted in an ACE-inhibition rate varying between 35 -61 % for the whey protein hydrolysates and 86 % for the casein hydrolysates, respectively. Two widely used industrial strains, L. delbrueckii subsp. bulgaricus and L. lactis subsp. cremoris can produce ACE-inhibitory peptides during milk fermentation. A 72-h incubation time was used to produce the fermented milks which, at least partly, explains the observed activity. The most inhibitory fractions of the fermented milk contained mainly β-casein-derived peptides with IC 50 -values from 8.0 to 11.2 µg/ml [90] . Belem et al. [91] fermented whey with Kluyveromyces marxianus var. marxianus, and identified a tetra peptide in the hydrolysate which had a sequence of β-lactorphin (Tyr-Leu-Leu-Phe). It was suggested that this peptide may have antihypertensive Milk protein-derived peptides which have been obtained by hydrolysis with digestive and/or microbial enzymes may affect the human immune system regulated by peripheral blood lymphocytes. Matar et al. [96] detected immunostimulatory peptides in milk fermented with a L. helveticus strain. Sütas et al. [97] demonstrated that digestion of casein fractions by both pepsin and trypsin produced peptides which in vitro had either immunostimulatory or immunosuppressive influence on human blood lymphocytes. Peptides derived from total casein and α s1 -casein were mainly suppressive, while those derived from β-and κ-casein were primarily stimulatory. When the caseins were hydrolysed by enzymes isolated from a probiotic Lactobacillus GG var. casei strain prior to pepsin-trypsin treatment, all hydrolysate fractions were immunosuppressive, and the highest activity was again found in α s1 -casein. These results suggest that lactic acid bacteria may modulate the immunogenicity of milk proteins prior or after oral ingestion of the product. This modulation may be beneficial in the down-regulation of hypersensitivity reactions to ingested proteins in patients with food protein allergy. Indeed, promising results have been obtained in the management of atopic reactions of infants by oral bacteriotherapy with the probiotic Lactobacillus GG strain [98] . These results are supported by a study of Laffieneur et al. [99] , who showed that β-casein hydrolysed by lactic acid bacteria, e.g., L. helveticus, has immunomodulatory activity which could be related to interaction with monocyte-macrophage and Thelper cells. Further studies are needed to elucidate the role of immunomodulatory milk protein peptides in the development of oral tolerance or allergy to milk proteins.
Hamel et al. [100] observed β-casomorphin immunoreactive material in cow's milk incubated with caseolytic strains, e.g., Pseudomonas aeruginosa or Bacillus cereus. The amount of β-casomorphin-4, -6 or -7 greatly exceeded β-casomorphin-5 immunoreactivity, indicating that some of this material represents authentic β-casomorphins and the rest consists more likely of β-casomorphin precursors. Furthermore, antioxidative peptides have been found after fermentation. For example, during L. delbrueckii subs. bulgaricus fermentation, an antioxidative peptide from κ-casein was formed. The DPPH radical scavenging activity of the peptide was lower than BHT, but in using the betacarotene decolorization system, the peptide showed about five times stronger antioxidative activity compared to BHT [101] .
Microbial enzymes have been used successfully for the production of bioactive peptides from milk proteins. Yamamoto et al. [43] reported that casein hydrolyzed by the cell wall-associated proteinase from L. helveticus CP790 showed antihypertensive activity in SHR. Several ACEinhibitory and one antihypertensive peptide were isolated from the hydrolysate. Using the same proteinase, Maeno et al. [44] identified a β-casein-derived antihypertensive peptide from the casein hydrolysate. The antihypertensive effect of this peptide (Lys-Val-Leu-Pro-Val-Pro-Gln) was dose-dependent in SHR at a dosage level from 0.2 to 2 mg of peptide per kg body weight. This peptide did not show a strong ACE-inhibitory activity as such, but a corresponding synthetic hexa-peptide-deleted by Gln (Lys-Val-Leu-ProVal-Pro)-exhibited strong ACE-inhibitory activity as well as a significant antihypertensive effect in SHR. It was suggested by these researchers that both the proline residue in the C-terminus and the amino acid sequence might be important for ACE-inhibition of the hexapeptide. Proline is generally known to be resistant to degradation by digestive enzymes.
OCCURRENCE OF BIOACTIVE PEPTIDES IN FOODS
Food proteins are susceptible to structural and chemical modifications during processing, and this may impact the profile of the peptides produced during subsequent digestion. Digestive enzymes react with structurally altered proteins, as they are various substrates. The influence of technological treatment of milk on gastrointestinal proteolysis has been demonstrated in minipigs [102, 103] , rats [104] and calves [105] [106] [107] . In addition, milk fermentation has been found to affect in vitro digestibility with trypsin [96] . Bioactive peptides may also be liberated during the manufacturing processes of milk products. Hydrolysed milk proteins used for hypoallergenic infant formulae, for clinical application and as food ingredients, for example, consist exclusively of peptides [108] . Proteases from food itself, such as plasmin in milk, can hydrolyse proteins during food processing and storage. Bacterial starter cultures contain several proteolytic enzymes which are responsible for the breakdown of protein into peptides and amino acids. Various studies have reported on casomorphins, ACE-inhibitory peptides and phosphopeptides found in fermented milk products ( Table 4) .
During cheese-ripening, a wide range of peptides are released, and many of them have been shown to have biological activities. Cheese contains phosphopeptides as natural constituents [109, 110] , and secondary proteolysis during cheese-ripening leads to the formation of other bioactive peptides such as those with ACE-inhibitory activity. In many studies, ACE-inhibitory activity has been found to be dependent on the cheese-ripening time. Meisel et al. [111] found higher ACE-inhibitory activities in middleaged Gouda cheese than in short-termed or long-termed ripened cheese. The results indicated that the activity in ripened cheese types increased during maturation, but decreases when the proteolysis exceeds a certain level. Furthermore, in products having a low degree of proteolysis, e.g., yoghurt, fresh cheese, quark, the ACE-inhibitory activity was low. These findings are consistent with the results obtained during "Festivo" cheese-ripening, showing that ACE-inhibitory peptides were maximally found in this cheese at the age of 13 weeks and declined thereafter [112] . The above results are supported by our analyses with regard to the occurrence of ACE-inhibitory activity in various Finnish cheese varieties (unpublished results). Saito et al. [113] found ACE-inhibitory activity in several cheeses and the highest activity was detected in Gouda cheese (at 24 months). In SHR experiments, the decrease in systolic blood pressure was statistically significant in four cheeses (Gouda , Blue, Edam and Havarti) at 6 h after gastric intubation. Several peptides were isolated and identified from 8 month old Gouda cheese, and two peptides [α s1 -casein f(1-9), β-casein f(60-68)] showed potent ACE-inhibitory activity with few antihypertensive effects. The α s1 -casein f(1-9), as well as shorter fragments derived from it, was also identified from "Festivo" cheese with ACE-inhibitory activity [112] . In the case of Manchego cheese, prepared from ovine milk, only cheese that was 15 days old showed comparatively low IC 50 -values [114] . Furthermore, the inhibitory activity decreased during the first 4 months, increased when proteolysis advanced, and decreased again in Manchego cheese aged 12 months. A total of 22 peptide fragments were identified in chromatographic fractions, the peptides corresponding to the sequences of ovine α s1 -, α s2 -and β-casein, respectively. In addition, Smacchi and Gobbetti [115] found that peptides from several Italian cheese varieties inhibited proteolytic enzymes of lactic acid bacteria and ACE. From Crescenza cheese, one peptide, β-casein f(58-72) inhibiting all the used enzymes including ACE was found. Muehlenkamp and Warthesen [116] found either no β-casomorphins at all in commercial cheese products, or the relevant concentration in the cheese extract was below 2 µg/ml. They further noted that the enzymatic degradation of β-casomorphins was influenced by a combination of pH and salt concentration at the cheese ripening temperature. Therefore, if formed in cheese, β-casomorphins may be degraded under conditions similar to Cheddar cheese-ripening. Precursors of β-casomorphins, on the other hand, have been identified in Parmesan cheese [117] . Matar and Goulet [118] detected β-casomorphin-4 in milk fermented with L. helveticus L89 deficient in X-prolyl-dipeptidyl-aminopeptidase. Sabikh and Mathur [119] detected a small quantity of β-casomorphin-3 in Edam cheese during ripening, whereas longer casomorphins were not detectable. These results confirm those found with Cheddar cheese, indicating that even if the casomorphins are formed in cheese, the enzymes present degrade them. These studies show that the presence of several Soy sauce X ACE-inhibitory [124] X = active peptides not identified bioactive peptides naturally formed in cheese depends on the equilibrium between their formation and degradation exerted by the proteolytic systems involved in cheese-ripening.
At present, at least two commercialised, fermented sour milk products contain ACE-inhibitory tripeptides, Val-ProPro (VPP) and Ile-Pro-Pro (IPP). These products are fermented with starter culture containing L. helveticus and S. cerevisiae [9] or L. helveticus LBK-16 H [120] . These milk products have antihypertensive effect in SHR, and also prevent the development of hypertension in SHR. Functional bioassays in rat vascular preparations showed that IPP possessed ACE-inhibitory activity at millimolar concentrations and VPP did not seem to possess ACEinhibitory activity. Thus, other mechanisms underlying the antihypertensive effect of milk peptides may be possible. In human studies with mildly hypertensive subjects, both milk products decreased systolic and diastolic blood pressure during the 8-week treatment period. No such influence was reported in subjects with normal blood pressure [121, 122] .
In addition to fermented milk products, other fermented food products have also been shown to have ACE-inhibitory activity. Fermented soybeans and fish sauces demonstrated strong ACE-inhibitory activity. One of the inhibitory substances in soy sauce is nicotianamine, derived from soybeans. Some fermented soyfoods, especially nattõ, contain other ACE-inhibitory substances produced during fermentation [123, 124] .
FUTURE APPLICATIONS OF BIOACTIVE PEPTIDES
The occurrence of many biologically active peptides in dietary proteins is now well-established. Numerous scientific, technological and regulatory issues have, however, to be resolved before these substances can be optimally exploited for human nutrition and health.
Firstly, there is a need to develop novel technologies, e.g., chromatographic and membrane separation techniques by means of which active peptide fractions can be produced and enriched [125] . Secondly, it is important to study the technological properties of the active peptide fractions and to develop model foods which contain these peptides and retain their activity for a certain period. It is recognized that peptides can be more reactive than proteins, due to their lower molecular weight, and the peptides that are present in the food matrix may react with other food components. The interaction of peptides with carbohydrates and lipids as well as the influence of the processing conditions (especially heating) on peptide activity and bioavailability should also be investigated [126] . In particular, possible formation of toxic, allergenic or carcinogenic substances, such as acrylamide or biogenic amines, warrants intensive research. To this end, modern methods need to be developed to study the safety of food stuffs containing biologically active peptides. In this context, microbial fermentation seems to be a potential natural technology applicable to the production of bioactive peptides either from animal or plant proteins. This potential is already well-demonstrated by the presence of bioactive peptides in fermented milks and cheese varieties.
Controlled fermentation of raw materials rich in proteins by known lactic acid bacteria strains may be developed on the commercial scale with respect to continuously operating fermentors or bioreactors. Alternatively, commercial production of specific peptide sequences could be enabled through recombined enzyme technology utilizing certain production strains, or through the use of purified proteolytic enzymes isolated from suitable microorganisms.
Furthermore, molecular studies are needed to assess the mechanisms by which the bioactive peptides exert their activities. This research area is currently considered as the most challenging one, due to the understanding that most known bioactive peptides are not absorbed from the gastrointestinal tract into the blood circulation. Their effect is, therefore, likely to be mediated directly in the gut lumen or through receptors on the intestinal cell wall. In this respect, the target function of the peptide concerned is of utmost importance. It is anticipated that in the near future such targets shall be the following lifestyle-related disease groups: a) cardiovascular diseases, b) cancers, c) osteoporosis, d) stress and d) obesity. Peptides derived from dietary proteins offer a promising approach to prevent, control and even treat such disease conditions through a regulated diet. 
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